Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway-Reference-Cited by-同舟云学术

Liraglutide ameliorates non-alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3-FOXO3a pathway

Published:2016-01-11 Issue:9 Volume:46 Page:933-943
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Tong Wenxin¹,Ju Liping¹,Qiu Miaoyan¹,Xie Qihai²,Chen Ying¹,Shen Weili²,Sun Weihong³,Wang Weiqing¹,Tian Jingyan¹

Affiliation:

1. Shanghai Clinical Center for Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrinology and Metabolism; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai China

2. Shanghai Institute of Hypertension; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai China

3. Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS); Chinese Academy of Sciences (CAS) and Shanghai Jiao Tong University School of Medicine; Shanghai China

Funder

National Key Program (973) for Basic Research of China

National Natural Science Foundation of China

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12634/fullpdf

Reference38 articles.

1. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis;Sonsuz;Am J Gastroenterol,2000

2. Current efforts and trends in the treatment of NASH;Ratziu;J Hepatol,2015